T2dm clinical trials

Explore recruiting t2dm clinical trials.

Recruiting t2dm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T2dm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.

Italy

Therapeutic use (Phase IV) EU CTIS Study details

A Multicentre, Randomized, Double-blind, Placebo-controlled, phase III study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

Austria

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial

Spain, Austria

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)

Germany, Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD

Italy, Norway, Germany, Greece, Netherlands, Denmark +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

T2dm trials by city

T2dm in Toronto T2dm in Vancouver T2dm in Montreal T2dm in Calgary T2dm in Edmonton T2dm in Ottawa T2dm in Winnipeg T2dm in Quebec City T2dm in Hamilton T2dm in Kitchener T2dm in London T2dm in Halifax T2dm in New York T2dm in Los Angeles T2dm in Chicago T2dm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease